It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
The NDA filing is supported by results from the phase III evERA Breast Cancer study
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
Subscribe To Our Newsletter & Stay Updated
